Abstract. Based on our microRNA (miRNA) expression signature analysis of maxillary sinus squamous cell carcinoma (MSSCC), we found that miR-1 and miR-133a were significantly reduced in tumor tissues. Quantitative real-time RT-PCR revealed that the expression levels of miR-1 and miR-133a were significantly downregulated in clinical MSSCC tumor tissues compared with normal tissues. We focused on the functional significance of miR-1 and miR-133a in cancer cells and identification of the novel cancer networks regulated by these miRNAs in MSSCC. Restoration of downregulated miRNAs (miR-1 or miR-133a) in cancer cells revealed that both miRNAs significantly inhibited cancer cell proliferation and induced cell apoptosis. Molecular target identification of these miRNAs showed that transgelin 2 (TAGLN2) and purine nucleoside phosphorylase (PNP) were regulated by miR-1 and miR-133a. Both TAGLN2 and PNP mRNA expression levels were significantly upregulated in clinical MSSCC tumor tissues. Silencing studies of target genes demonstrated that both genes inhibited cancer cell proliferation. The identification of novel miR-1/miR133a-regulated cancer pathways could provide new insights into potential molecular mechanisms of MSSCC oncogenesis.
Introduction
The maxillary sinuses are single pyramidal cavities in the bodies of the maxillae. Squamous cell carcinoma is the most common cancer of the maxillary sinus (60-70%), followed by adenoid cystic carcinoma (1) . Maxillary sinus squamous cell carcinoma (MSSCC) comprises 2-3% of all head and neck tumors and the annual incidence is 0.5-1.0 per 100,000 people (2, 3) . Clinical symptoms of MSSCC present insidiously, and sometimes resemble those of chronic sinusitis. Although presentation of lymph node and/or distant metastasis is uncommon, primary tumors are often diagnosed as advanced disease. The five-year survival rate of T4 tumors is approximately 50%. Local recurrence is the most common cause of treatment failure and death (2) (3) (4) .
From an epidemiologic standpoint, occupational exposures to leather, wood dust, nickel, arsenic and formaldehyde have been implicated in the etiology of MSSCC (5, 6) . In contrast, tobacco, a major risk factor for head and neck squamous cell carcinoma (HNSCC), does not play an important role in MSSCC (7, 8) . It has been suggested that the molecular mechanism of carcinogenesis differ for these two cancers. Thus far, there have been few genome-wide gene expression analyses of MSSCC. Furthermore, analysis of microRNA (miRNA) has not been conducted for this disease.
miRNAs are a class of small non-coding RNA molecules consisting of [19] [20] [21] [22] nucleotides that have an important role in a variety of biological processes including development, differentiation, apoptosis, and cell proliferation. They regulate gene expression through translational repression and mRNA cleavage (9) . Bioinformatic predictions indicate that miRNAs regulate more than 30% of protein coding genes (10) . So far, 1048 human miRNAs have been registered at miRBase release 16.0 (http://microrna.sanger.ac.uk/). Although biological functions of miRNAs remain mostly unknown, recent studies suggest that miRNAs contribute to the initiation and development of various types of cancer (11) . miRNAs can be separated into two classes: those which are oncogenic and those which are tumor suppressive. Overexpressed miRNAs could act as oncogenes by repressing tumor suppressor genes, whereas under-expressed miRNAs could function as tumor suppressors by negatively regulating oncogenes (12 Our previous studies of miRNA expression signatures showed that miR-1 and miR-133a were frequently downregulated in various cancer cells (13, 14 (15) . Furthermore, the miR-15a-16-1 cluster is known to act as a tumor suppressor by targeting multiple oncogenes, such as BCL2, MCL1, CCND1 and WINT3A (16) . We have focused on the function of clustered miRNAs and the identification of target genes (14) . The functional analysis of clustered miRNAs is important in the field of cancer research.
The aim of this study was to clarify the functional significance of miR-1 and miR-133a in MSSCC and to identify cancer pathways regulated by those miRNAs. For target gene searches of miR-1 and miR-133a in MSSCC cells, we performed genomewide gene expression analysis. We focused on two genes as candidate common targets of miR-1 and miR-133a in this study, as those were among the most down-regulated genes. Insights into the association between tumor suppressive miRNAs and their target oncogene networks could enhance our understanding of the molecular mechanism of MSSCC carcinogenesis.
Materials and methods
Clinical MSSCC specimens. Written consent for tissue donation for research purposes was obtained from each patient before tissue collection. The protocol was approved by the Institutional Review Board of Chiba University. Twenty pairs of primary tumor tissues and corresponding normal epithelial tissues were obtained from patients with MSSCC in Chiba University Hospital (Chiba, Japan) from 2007 to 2010. The normal tissue was confirmed to be free of cancer cells by pathologic examination. The specimens were immersed in RNAlater (Qiagen, Valencia, CA, USA) and stored at -20˚C until RNA was extracted.
MSSCC cell culture. The human MSSCC cell line, IMC-3 (17), was used. Cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 37˚C.
RNA isolation. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's protocol. RNA concentrations were determined spectrophotometrically, and molecular integrity was checked by gel electrophoresis. RNA quality was confirmed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).
Mature miRNA transfection and small interfering RNA treatment. The following RNA species were used in this study: mature miRNAs, Pre-miR™ miRNA Precursors (hsa-miR-1; Pre-miR ID: PM10633, hsa-miR-133a; Pre-miR ID: PM10413), negative control miRNA (P/N: AM17111) (Applied Biosystems, Foster City, CA, USA), small interfering RNA (Stealth Select RNAi™ siRNA; si-transgelin 2 (TAGLN2) Cat#; HSS144746, si-purine nucleoside phosphorylase (PNP) Cat#; HSS107264) (Invitrogen) and negative control siRNA (Stealth™ RNAi Negative Control Medium GC Duplex; 12935-300) (Invitrogen).
RNAs were incubated with Opti-MEM (Invitrogen) and Lipofectamine™ RNAiMax reagent (Invitrogen) as described previously (18) . The transfection efficiency of Pre-miR™ in the cell line was confirmed based on down-regulation of TWF1 (PTK9) mRNA following transfection with miR-1 as previously reported (13, 19) .
Cell proliferation assays. Cells were transfected with 10 nM miRNA and siRNA by reverse transfection and plated in 96-well plates at 3x10 3 cells per well. After 72 or 96 h, cell proliferation was determined by the XTT assay, using the Cell Proliferation kit II (Roche Molecular Biochemicals, Mannheim, Germany) as previously reported (13, 19) . Triplicate wells were measured for cell viability in each treatment group. 
Target gene search for miR-1 and miR-133a.
A genome-wide screen using miR-1 or miR-133a transfectants was performed to identify their target genes in the IMC-3 cells. Oligo-microarray human 44K (Agilent Technologies) was used for expression profiling of the transfectants in comparison with a miRNAnegative-control transfectant. Hybridization and wash steps were performed as previously described (20) . The arrays were scanned using a Packard GSI Lumonics ScanArray 4000 (Perkin Elmer, Boston, MA, USA). The data were analyzed by means of DNASIS array software (Hitachi Software Engineering, Tokyo, Japan), which converted the signal intensity for each spot into text format. The log2 ratios of the median subtracted background intensities were analyzed. Data from each microarray study were treated by a global normalization method. Predicted target genes and their target miRNA binding site seed regions were investigated using TargetScan (release 5.1, http://www.targetscan.org/). The sequences of the predicted mature miRNAs were confirmed using miRBase (release 16.0, http://microrna.sanger.ac.uk/).
Quantitative real-time RT-PCR. First-strand cDNA was synthesized from 1 µg of total RNA using a High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Gene-specific PCR products were assayed continuously using a 7900-HT RealTime PCR System according to the manufacturer's protocol. The initial PCR step consisted of a 10-min hold at 95˚C, followed by 40 cycles consisting of a 15 sec denaturation at 95˚C and a 1 min annealing/extension at 63˚C. TaqMan ® probes and primers for TAGLN2 (P/N: Hs00761239_s1), PNP (P/N: Hs00165367_m1) and GUSB (P/N: Hs99999908_m1) internal control were obtained from Applied Biosystems (Assay-On-Demand Gene Expression Products). The expression levels of miR-1 (Assay ID: 002222) and miR-133a (Assay ID: 002246) were analyzed by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay; Applied Biosystems) and normalized to RNU48 (Assay ID: 001006). All reactions were performed in triplicate, and included negative control reactions that lacked cDNA.
Immunoblotting. Cells were harvested 72 h after transfection and lysates were prepared. Each cell lysate (50 µg of protein) was separated by NuPAGE on 4-12% bis-tris gels (Invitrogen) and transferred to PVDF membranes. Immunoblotting was performed with diluted (1:250) polyclonal TAGLN2 antibody (HPA001925) and polyclonal PNP antibody (HPA001625) (Sigma-Aldrich, St. Louis, MO, USA), with β-actin antibody (sc-1615; Santa Cruz Biotechnology, Santa Cruz, CA, USA) used as an internal control. The membrane was washed and incubated with goat anti-rabbit IgG (H+L)-HRP conjugate (BioRad, Hercules, CA, USA). Specific complexes were visualized by echochemiluminescence (GE Healthcare Bio-Sciences, Princeton, NJ, USA), and the expression levels of these proteins were evaluated by ImageJ software (ver.1.43; http://rsbweb.nih. gov/ij/index.html).
Statistical analysis. The relationships between two groups and the numerical values obtained by real-time RT-PCR were analyzed using the non-parametric Mann-Whitney U test or the paired t-test. The relationship among more than three variables and numerical values was analyzed using the Bonferroni adjusted Mann-Whitney U test. Spearman's rank test was used to evaluate the relationships among the relative expression levels of miR-1, miR-133a, TAGLN2 and PNP mRNA. All analyses were performed using Expert StatView (version 4, SAS Institute Inc., Cary, NC, USA).
Results

miR-1 and miR-133a are down-regulated in clinical MSSCC
specimens. Data characterizing 20 MSSCC patients are presented in Table Ι . We first confirmed that expression levels of miR-1 and miR-133a were significantly down-regulated in clinical MSSCC tumor tissues compared with normal tissues (p=0.0023 and p=0.0382, respectively, Fig. 1A) . A significant positive correlation was shown between expression of miR-1 and miR-133a (Fig. 1B) .
Effect of miR-1 and miR-133a on cell proliferation and apoptosis in IMC-3 cells.
The XTT assay showed statistically significant inhibition of cell proliferation in miR-1 and miR-133a transfectants compared with miRNA controls after 72 and 96 h. For example, after 72 h, miR-1 and miR-133a transfected IMC-3 cultures grew 59% and 90%, respectively, as much as mock cultures (p<0.0001 and p=0.0051, respectively), moreover after 96 h, proliferation cell to 27% and 62% of mock, respectively (both p<0.0001, Fig. 2A) .
Cell apoptosis in miR-1 and miR-133a transfected cells was assessed by flow cytometry. The fraction of early apoptotic cells significantly increased in miR-1 transfectants approximately 6.4-fold and in miR-133a transfectants approximately 2.7-fold compared with mocks (both p<0.0001, Fig. 2B ).
Gene expression profiling identifies down-regulated genes in miR-1 and miR-133a transfectants.
To investigate candidate molecular targets of miR-1 and miR-133a in MSSCC cells, we examined the effects of miR-1 and miR-133a on protein coding genes. Mature miR-1 or miR-133a was transiently transfected clearly showed changes in gene expression patterns between both miR-1 and control transfectants, and miR-133a and controls. To identify common candidate target genes of miR-1 and miR-133a, a cut-off of fold-change value more than -1.5 (Log2 ratio) was applied to the array data. This filter resulted in the identification of 23 genes that were significantly downregulated upon miR-1 or miR-133a transfection in IMC-3 cells (Table II) . Entries from the microarray data were approved by the Gene Expression Omnibus (GEO), and were assigned GEO accession number GSE26032. The 3' UTR of these down-regulated genes were examined for miR-1 and miR-133a target sites using the TargetScan database. Of the 23 putative gene targets, six genes contained miR-1 and miR-133a common target sites.
Expression levels of candidate target genes of miR-1 and miR133a in MSSCC clinical specimens.
We measured the mRNA expression levels of six candidate genes in 20 of clinical MSSCC specimens by quantitative real-time RT-PCR. Two genes, TAGLN2 and PNP were significantly up-regulated in MSSCC tumor tissues (p=0.0321 and p=0.0089, respectively, Fig. 3A and B, left). The other four genes (C4orf34, PXDN, SLC16A6 and STXBP4) were not up-regulated in MSSCC tumor tissues (data not shown). There were significant inverse correlations between TAGLN2 -miR-1, TAGLN2 -miR-133a and PNP -miR-1. There was a trend but no significant inverse correlation between PNPmiR-133a (Fig. 3A and B, middle and right).
TAGLN2 and PNP mRNA and protein levels are repressed by miR-1 and miR-133a.
The qRT-PCR analysis showed that the mRNA expression levels of TAGLN2 and PNP in the IMC-3 cell line were 2.7-fold and 1.5-fold higher, respectively, than those in normal epithelia (data not shown). We performed gain-offunction studies using miR-1 and miR-133a transfected IMC-3 cells, and the mRNA and protein expression levels of TAGLN2 and PNP were markedly down-regulated in the transfectants in comparison with the mock controls ( Fig. 4A and B) . Silencing TAGLN2 and PNP inhibits cell proliferation of IMC-3 cells. We performed loss-of-function studies using si-TAGLN2 and si-PNP transfected IMC-3 cells. The expression levels of the mRNAs and proteins were repressed by si-TAGLN2 and si-PNP ( Fig. 5A and B, left and middle). XTT assays revealed that cell proliferation was only 59% of mock control levels in si-TAGLN2 transfectants and 75% of mock controls in si-PNP transfectants ( Fig. 5A and B, right) .
Discussion
In the field of cancer research, evidence has been accumulating that aberrant expression of miRNAs and uncontrolled gene expression of tumor suppressors and oncogenes contribute to the development of human cancers (21) . We performed the first miRNA expression signature analysis of MSSCC using clinical specimens. Our data showed that miR-1 and miR-133a were significantly down-regulated in cancer cells. We validated the reduction of both miR-1 and miR-133a in 20 specimens of MSSCC in this study. It is suggested that this event is a key step in oncogenesis of MSSCC. To confirm the importance of this observation, we investigated the functional significance of miR-1 and miR-133a in IMC-3 cells. Our present data revealed that restoration of miR-1 or miR-133a expression suppressed cancer cell proliferation and promoted apoptosis in IMC-3 cells.
As for the relation of human cancers and miR-1, recent articles revealed that miR-1 induced apoptosis through repression of Mcl-1 in lung cancer (22) . miR-1 also targets c-Met in rhabdomyosarcoma (23) . Consistent with these reports, our previous studies revealed that miR-1 was down-regulated in cancer and acts as a tumor suppressor (14, 24) .
With regard to miR-133a, several reports showed that miR133a was under-expressed in pancreatic ductal adenocarcinoma, colorectal carcinoma, tongue squamous cell carcinoma (SCC), and rhabdomyosarcoma (25) (26) (27) (28) . miR-133a inhibited cell proliferation and induced apoptosis and directly bound to oncogenic PKM2 in tongue SCC (27) . Our research also revealed that miR-133a was repressed in the tumor and had tumor suppressive functions (13, 29) . Taken together, miR-1 and miR-133a are important miRNAs acting as tumor suppressors in human cancers.
Of particular interest is the fact that one miRNA regulates many protein-coding genes. However, the nature of mRNAmicroRNA networks in the human genome is unclear. The elucidation of new regulatory networks in cancer is important for understanding carcinogenesis. Therefore, we are continuing our investigation of tumor suppressive miRNA-regulated oncogenic targets in various cancer cells (13, 14, 19, 24, 29) . In this study, we adopted a method of genome-wide gene expression analysis in IMC-3 cells, using miR-1 or miR-133a transfectants to identify targets. We identified genes regulated by miR-1 or miR-133a by analyzing the expression profiles. This approach led us to investigate the mRNA expression levels of six candidate genes (TAGLN2, C4orf34, PXDN, SLC16A6, STXBP4 and PNP) using MSSCC clinical specimens. Our criteria for selection in this analysis were that candidate genes had to be up-regulated in cancer cells. Two genes (TAGLN2 and PNP) were chosen according to this standard.
TAGLN2 is a member of the calponin family of actinbinding proteins. TAGLN and TAGLN3 are homologues of TAGLN2, and TAGLN3 is a novel neuron-specific protein (30, 31) . The protein encoded by the TAGLN gene is an actinbinding protein like TAGLN2, found in fibroblasts and smooth muscle (32) . Overexpression of TAGLN2 was observed in hepatocellular carcinoma, lung adenocarcinoma, and pancreatic cancer (33) (34) (35) (36) . More recently, we also found overexpression of TAGLN2 in HNSCC and bladder cancer (14, 24) . Furthermore, we proved that miR-1 and/or miR-133a function as tumor suppressors and directly regulate TAGLN2 in cancer cells (14, 24) . The results of our MSSCC study are in accord with past reports. Reduction of miR-1 and/or miR-133a expression levels and the increase of TAGLN2 appear causally related, suggesting that novel pathways in cancer cells play important roles in human carcinogenesis. However, it is still unknown how TAGLN2, an actin-binding protein, contributes to cell proliferation, which should be investigated by further analysis.
Our analysis suggests that overexpression of PNP has an important role in MSSCC carcinogenesis. PNP is an enzyme involved in purine metabolism. PNP catalyzes the conversion of adenosine to adenine, inosine to hypoxanthine, and guanosine to guanine, creating ribose phosphate in each case. PNP is considered a therapeutic target in malignant lymphoproliferative diseases. This is based on studies of genetic PNP-deficiency syndrome in which 2'-deoxyguanosine accumulates in plasma and deoxyguanosine triphosphate (dGTP) in lymphocytes, accordingly leading to dGTP-directed inhibition of DNA synthesis and cell death (37) . Forodesine (BCX-1777) is a novel PNP inhibitor which induces apoptosis of chronic lymphocytic leukemia (CLL) cells (38 advanced, Fludarabine-refractory CLL (39) . Silencing PNP inhibited proliferation of IMC-3 cells in our present study. PNP inhibition might be a potential strategy for novel treatment of MSSCC.
In conclusion, miR-1 and miR-133a were frequently reduced in MSSCC cancer cells. Both of the miRNAs may function as tumor suppressors regulating several oncogenic genes such as TAGLN2 and PNP in MSSCC. Both TAGLN2 and PNP were up-regulated in MSSCC specimens. The miR-1/miR-133a cluster regulates novel cancer pathways and as such could provide new insights into molecular mechanisms of MSSCC. Further studies could contribute to the development of new therapeutic strategies for this disease. . Western blots revealed that TAGLN2 protein was also decreased in si-TAGLN2 (middle). Cell growth as revealed by the XTT assay after 72 h (right). * p<0.0001 (B) RT-PCR revealed that PNP mRNA was markedly repressed in si-PNP (left). Western blots revealed that PNP protein was also decreased in si-PNP (middle). Cell growth as revealed by the XTT assay after 72 h (right). * p=0.0140, ** p<0.0001.
